To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.
NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.
Shilajit elicits apoptosis and suppresses cell migration in oral cancer cells through targeting Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) and chemokine signaling pathways
Shilajit (Mumio) is a humic substance with a dark brown colour that comes from rocks found at high altitudes. For centuries, shilajit has been a widely employed traditional medicinal remedy to address various physical ailments. Given the prevalence of oral cancer, there is a growing need for more effective therapies in its treatment.
In this in vitro study, the impact of shilajit on normal human gingival fibroblast cells (hGFs) and oral cancer cells (KB-1, subline of the KERATIN-forming tumor cell line HeLa) was compared. The MTT and Annexin-V tests were used to measure the KB-1 cells growth and apoptosis after they were exposed to varying concentrations of Shilajit for 24h. An inverted microscope was used to evaluate the shilajit treated cell morphology. On the other hand, AO/EtBr dual staining was employed to analyse cellular apoptosis quantitatively. ROS production analysis was carried out utilizing DCFH-DA staining, while the gene expression of proapoptotic and antiapoptotic proteins was assessed through real-time PCR.